DGAP-News: Heidelberg Pharma AG / Key word(s): Conference
09.04.2018 / 09:01
The issuer is solely responsible for the content of this announcement.
Heidelberg Pharma Presents Proprietary ATAC Technology Platform at Two Scientific Conferences
Ladenburg, Germany, 9 April 2018 – Heidelberg Pharma AG (FWB: WL6) today announced that they will present their proprietary ATAC technology platform at two upcoming scientific conferences.
6th Annual Antibodies & Antibody Drug Conjugates Conference
Professor Andreas Pahl will present the following speech on Monday, 9 April 2018 at 11.40 a.m. BST:
Antibody Targeted Amanitin Conjugates (ATACs) – Expanding the ADC landscape with a new payload targeting RNA Polymerase II
AACR Annual Meeting 2018
Heidelberg Pharma will announce scientific data in the course of two poster presentations. One poster shows structure-effect relationships for synthetic variants of Amanitin-linker molecules which are particularly suitable for the treatment of solid tumors. The other poster shows preclinical data of an ATAC which is directed to PSMA. This protein is relevant inter alia for prostate cancer.
Details of the presentations:
Structure-Activity relationship of Linker-Amanitin variants and optimization of Linker-Amanitin derivatives for the treatment of solid tumors
Preclinical evaluation of an anti-PSMA antibody-targeted Amanitin conjugate
The abstracts of the presentations are available on the website of AACR: http://www.abstractsonline.com/pp8/#!/4562/presentation/2997 and http://www.abstractsonline.com/pp8/#!/4562/presentation/3002.
About Heidelberg Pharma’s proprietary ATAC technology
About Heidelberg Pharma
The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R), while RENCAREX(R) is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
09.04.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||Heidelberg Pharma AG|
|Schriesheimer Str. 101|
|Phone:||+49 (0)89 41 31 38 – 0|
|Fax:||+49 (0)89 41 31 38 – 99|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|